Pharmaceutical - Pharmaceutical, Major

Filter

Current filters:

PharmaceuticalMajor

Popular Filters

1 to 25 of 26 results

Novartis to start production of Tasigna in Russia

Novartis to start production of Tasigna in Russia

19-08-2014

Russia’s largest drugmaker Pharmstandard has signed an agreement with Swiss pharma major Novartis on…

CancerCytokinesHealth Medical PharmaIgor KrylovMajorNovartisOncologyPharmaceuticalPharmstandardProductionRussiaTasigna

Sanofi and Regeneron purchase FDA priority voucher for alirocumab

Sanofi and Regeneron purchase FDA priority voucher for alirocumab

31-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals intend to use a US Food…

alirocumabBioMarin PharmaceuticalFranceMajorPharmaceuticalRare diseasesRare pediatric diseasesRegeneronRegeneron PharmaceuticalsRegulationSanofiUSA

Sanofi posts strong 2nd-qtr earnings, beating estimates

Sanofi posts strong 2nd-qtr earnings, beating estimates

31-07-2014

French pharma major Sanofi this morning reported that group sales for the second quarter of 2014 grew…

FinancialFranceGaucherGenzymeInsulin glargineMajorMiddle EastPharmaceuticalSanofi

Roche joins forces with AmorChem on Steinert’s disease research

Roche joins forces with AmorChem on Steinert’s disease research

29-07-2014

Swiss drug major Roche and AmorChem, a Canadian venture capital firm investing in life science projects,…

AmorChemCanadaEnabling technologyEuropean UnionLicensingMajorMuscular dystrophyMyotonic dystrophyPharmaceuticalRare diseasesResearchRocheSwitzerland

New treatments to boost hepatitis C market to $19.2 billion by 2016

New treatments to boost hepatitis C market to $19.2 billion by 2016

24-06-2014

The launch of interferon-free regimens is expected to boost the hepatitis C market from $2.9 billion…

Anti-viralsAntiviralsBusiness FinanceCytokinesDatamonitorGilead SciencesGlobalMajorMarkets & MarketingPharmaceuticalSovaldi

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16-06-2014

UK pharma major GlaxoSmithKline announced the results from the Phase III PETIT2 study evaluating the…

eltrombopagEuropeGlaxoSmithKlineHealth Medical PharmaHematologyItalyMajorMedicinePharmaceuticalResearchThrombocytopenic purpura

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

15-06-2014

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide),…

Anti-diabetic drugsDiabetesGlaxoSmithKlineGSKMajorPharmaceuticalResearchStudy protocolStudy protocolTanzeumUK

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

12-06-2014

Anglo-Swedish pharma major AstraZeneca has signed a global licence accord with Synairgen, an AIM-listed…

AstraZenecaChronic lower respiratory diseasesHealth Medical PharmaLicensingMajorMedicinePharmaceuticalPulmonologyRespiratory and PulmonarySNG001Synairgen

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial

12-06-2014

US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

Novartis’ Glivec could lose half patient population in China to generics

Novartis’ Glivec could lose half patient population in China to generics

03-06-2014

Hematologists in China estimate that Glivec (imatinib) from Swiss drug major Novartis will lose nearly…

Blast phase CMLChemistryChinaChronic phase CMLGlivecHealth Medical PharmaHematologyMajorMarkets & MarketingNovartisPharmaceutical

Forest appeases shareholders over Actavis deal

30-05-2014

US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

Positive top-line results for MedImmune RA and lupus treatments

Positive top-line results for MedImmune RA and lupus treatments

13-05-2014

Anglo-Swedish drug major AstraZeneca has announced that two key molecules in its global biologics R&D…

Anti-Arthritics/RheumaticsAstraZenecaBahija JallalHealthHealth Medical PharmaMajorMedicineMedImmunePharmaceuticalResearchUK

Novartis presents real world data for Lucentis

Novartis presents real world data for Lucentis

09-05-2014

Swiss drug major Novartis has reported data on the eye drug Lucentis (ranibizumab) at the 2014 Association…

AMDEuropeHealthLucentisMajorMedicineNovartisOphthalmicsOphthalmologyPharmaceuticalResearch

US FDA approves GSK’s Incruse Ellipta for COPD

US FDA approves GSK’s Incruse Ellipta for COPD

01-05-2014

The US Food and Drug Administration has approved UK pharma major GlaxoSmithKline’s Incruse (umeclidinium)…

Chronic lower respiratory diseasesCOPDGlaxoSmithKlineIncruseIncruse ElliptaMajorMedicinePharmaceuticalPulmonologyRegulationRespiratory and PulmonaryUKUSA

AAN 2014: Genzyme’s Lemtrada slows brain atrophy in MS patients

AAN 2014: Genzyme’s Lemtrada slows brain atrophy in MS patients

01-05-2014

French drug major Sanofi and its subsidiary Genzyme presented positive new data from the Lemtrada (alemtuzumab)…

Autoimmune diseasesFranceGenzymeHealthLemtradaMajorMRIMultiple sclerosisNeurologicalPharmaceuticalResearch

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

GSK faces bribery allegations in Poland

GSK faces bribery allegations in Poland

14-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribing doctors in Poland, according to the…

BBCGlaxoSmithKlineGSK regional managerLegalMajorMedicinePharmaceuticalPolandPulmonologyRespiratory and PulmonarySeretideUK

Tamiflu use called into question by UK report

Tamiflu use called into question by UK report

10-04-2014

The UK government and health policy decision makers are being called upon to review the guidance on the…

Antibiotics and Infectious diseasesChemistryDavid ToveyGlaxoSmithKlineHealthcareMajorPharmaceuticalRelenzaResearchRocheTamifluThe British Medical JournalUKUK government

Takeda ordered to pay $6 billion damages in Actos trial

Takeda ordered to pay $6 billion damages in Actos trial

08-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical has been ordered to pay $6 billion in punitive damages…

ActosDiabetesEli Lilly and CompanyJapanJudgeLegalMajorPharmaceuticalPyridinesTakeda NycomedThiazolidinedionesUSA

1 to 25 of 26 results

Back to top